New research indicates potential cancer risk reduction from diabetes and obesity drugs, though evidence is mostly observational.
Texas: (RightNow) New evidence suggests that GLP-1 medications used for diabetes and obesity treatment may reduce cancer risk. Drugs like Ozempic and Wegovy show a decrease in recurrence rates for certain cancer types.
At the American Society of Clinical Oncology Conference 2026, Dr. Lauren Rourke highlighted the link between GLP-1 drug use and lower breast cancer recurrence rates. Current evidence is primarily based on observational studies.
Experts state it is uncertain if GLP-1 drugs directly reduce cancer risk. These medications may lead to weight loss and reduced chronic inflammation. Lower body fat can decrease estrogen levels.
These factors are considered linked to the risk of certain breast cancers. The study’s findings pave the way for further research on the connection between GLP-1 drugs and cancer. Randomized and controlled clinical trials are needed.
It is important to note that individuals should only use GLP-1 medications for cancer prevention or treatment under a doctor’s guidance. Experts warn against self-medication.
